Jada Bascom Foundation
All conditions

Autoimmune conditions

Early diffuse cutaneous systemic sclerosis

Also called: SSc · dcSSc · early dcSSc · systemic scleroderma · scleroderma · systemic sclerosis · Progressive systemic sclerosis · Diffuse cutaneous systemic sclerosis

What a donor has to do with this

A stem cell transplant is common for this condition, but it almost always returns the person’s own cells, collected in advance. No donor is involved. This is the part of transplantation most people have never heard about.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

What the evidence says

Who it affects
The UK NHS profile accessed in 2026 describes the broader systemic-sclerosis population—not specifically early diffuse cutaneous disease—as mostly affecting women, usually developing at ages 30–50, and rare in children.
Treatments other than a transplant
Mycophenolate mofetil, cyclophosphamide, rituximab, and organ-specific immunosuppression are used for skin/lung disease.; Nintedanib (US 2019 for SSc-associated interstitial lung disease) and tocilizumab (US 2021 for SSc-ILD) are important non-transplant options.; Pulmonary-hypertension vasodilators and renal-crisis, gastrointestinal, vascular, and rehabilitation care address organ complications.
If a transplant is used, the cells come from
autologous mobilized peripheral-blood stem cells (dominant contemporary source); CD34-selected or unmanipulated autologous peripheral-blood grafts; bone marrow: not reported in the opened disease-specific sources; cord blood: not reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Benefit in randomized trials coexists with early treatment-related risk; occult cardiac involvement can make mobilization/conditioning dangerous.; This row is restricted to early diffuse cutaneous systemic sclerosis; limited cutaneous, sine-scleroderma, late stable diffuse, and other SSc forms do not inherit its HCT claims and require separate evidence assessment.; Conditioning intensity and CD34 selection differed across ASSIST, ASTIS, and SCOT, so there is no single universally superior platform.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“auto-HCT is superior to CY for early rapidly progressive SSc”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

We are not asking you to register on this page

A transplant for this condition almost always uses the person’s own cells, so a donor would make no difference to it. Registries do need people — just not for this. Other conditions in the library are a different story.

What a transplant using your own cells involves

Related conditions

Others in autoimmune conditions. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from

Early diffuse cutaneous systemic sclerosis — what it is and how it is treated | Jada Bascom Foundation